Clinical trial · Interventional
Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas
NCT06455189CI-TRIAL-00116429withdrawnPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated IRB
Summary
Brief summary (as posted)
Magnetic resonance imaging, MRI, is a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body. The goal of this study is to determine if MR fingerprinting, new way of acquiring MRI images, can help identify the extent of tumor spread in the brain, better than routine MRI images.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control Group - Standard of care neurosurgical resection | Other | — | UNRESOLVED |
| MRF/MRI infiltration guidance for extended resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Group 1
- description
- Routine standard of care process will be followed for neurosurgical guidance
- interventionNames
- Other: Control Group - Standard of care neurosurgical resection
- type
- EXPERIMENTAL
- label
- Group 2
- description
- The surgeon will have access to advanced MRI and MRF analysis research images during surgery and may use them for guidance, in addition to all routinely used surgical tools.
- interventionNames
- Procedure: MRF/MRI infiltration guidance for extended resection
Primary outcomes (3)
- measure
- Number of participants who experienced serious adverse events(SAEs) at 48 hours post targeted biopsy sampling procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Stage I: Inclusion criteria: * Age \> 18 * MR imaging findings suggestive of GB * Maximal tumor diameter greater than 3 cm * Ability to provide written informed consent * Ability to undergo MRI scan * Consideration for biopsy, subtotal or gross total resection. Exclusion Criteria: * Contraindications to MRI * Contraindication to surgical treatment * Prior treatment for glioblastoma Stage II: Inclusion Criteria: * Age \> 18 * MR imaging findings suggestive of GB * Maximal tumor diameter greater than 3 cm * Ability to provide written informed consent * Ability to undergo MRI scan * Lesions amenable to gross total resection * Presence of peritumoral FLAIR signal abnormality beyond the area of enhancement. Exclusion Criteria: * Inability to undergo MRI imaging * Participants undergoing only stereotactic biopsy or less than gross total resection * Participants undergoing LITT * Inability to consent for the study * Previously treated/ recurrent glioma.
References
Publications (0)
Data not yet available
No reference posted for this study.